Stem Cells Therapy as a Possible Therapeutic Option in Treating COVID-19 Patients.

Content Provider	Europe PMC
Author	Esquivel, Diana Mishra, Rangnath Soni, Prabhat Seetharaman, Rajasekar Mahmood, Anjum Srivastava, Anand
Abstract	An unfortunate emergence of a new virus SARS-CoV-2, causing a disease known as COVID-19, has spread all around the globe and has caused a pandemic. It primarily affects the respiratory tract and lungs in some cases causing severe organ damage and pneumonia due to overwhelming immune responses. Clinical reports show that the most commons symptoms are fever, dry cough, and shortness of breath, along with several other symptoms. It is thought that an immense cytokine dysregulation in COVID-19 patients is caused following the virus infection. Notably, if patients present with pre-existing specific comorbidities like diabetes or high blood pressure, rates of COVID-19 induced complications and deaths are escalated. Mesenchymal stem cell (MSC) therapy has been shown to alleviate pneumonia and acute respiratory syndrome (ARDS) symptoms, through their immunomodulatory activities in COVID-19 patients. Although more research studies and clinical trial results are needed to elucidate the exact mechanism by which MSCs provide relief to COVID-19 infected patients. Results from clinical trials are encouraging as patients treated with MSCs, regain lung functions and have restored levels of cytokines and trophic factors underscoring the fact that stem cell therapy can be, at least, a complementary therapy to alleviate sufferings in COVID-19 patients. This review discusses the possible therapeutic uses of MSCs for treating COVID-19.Graphical Abstract
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7395577&blobtype=pdf
ISSN	26293269
Journal	Stem Cell Reviews and Reports [Stem Cell Rev Rep]
Volume Number	17
DOI	10.1007/s12015-020-10017-6
PubMed Central reference number	PMC7395577
Issue Number	1
PubMed reference number	32740890
e-ISSN	26293277
Language	English
Publisher	Springer US
Publisher Date	2021-02-01
Publisher Place	New York
Access Restriction	Open
Rights License	This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. © Springer Science+Business Media, LLC, part of Springer Nature 2020
Subject Keyword	COVID-19 Immunomodulation Mesenchymal stem cells (MSCs) MSCs' immunomodulatory properties Lymphocytes SARS-CoV-2
Content Type	Text
Resource Type	Article
Subject	Cell Biology Cancer Research